Valeant Pharmaceuticals International Inc (NYSE:VRX)

225.13
BATS BZX Real-Time Price
As of 1:58pm ET
 -3.36 / -1.47%
Today’s Change
106.00
Today|||52-Week Range
246.01
+57.31%
Year-to-Date
The Zacks Analyst Blog Highlights: Conns, Valeant Pharmaceuticals, Trinseo, Nordic Am...
Jul 02 / Zacks.com
McKesson Keeps FY16 Earnings View, Acquisitions Hold Key - Analyst Blog
Jun 25 / Zacks.com
5 Best Stocks of the First Half of 2015 - Analyst Blog
Jul 01 / Zacks.com
RedHill Biopharma (RDHL) Jumps: Stock Up 8.8% - Tale of the Tape
Jun 25 / Zacks.com
Sears, Valeant Pharmaceuticals, Kinder Morgan: 3 Stocks Insiders Love
Jul 01 / TheStreet.com
Alnylam Reports Encouraging New Data on Hemophilia Drug - Analyst Blog
Jun 24 / Zacks.com
AMAG Down on Cord Blood Registry Deal for $700 Million - Analyst Blog
Jun 30 / Zacks.com
Synta Reports Encouraging Preclinical Data on Ganetespib - Analyst Blog
Jun 24 / Zacks.com
BioMarin's NDA for DMD Drug Drisapersen Accepted by FDA - Analyst Blog
Jun 30 / Zacks.com
Valeant-Progenics Report NDA Filing for Oral Relistor in US - Analyst Blog
Jun 24 / Zacks.com
Regeneron/Bayer's Eylea Gets Label Expansion in Japan - Analyst Blog
Jun 29 / Zacks.com
BioLineRx (BLRX) Shows Strength: Stock Rises 7.4% - Tale of the Tape
Jun 24 / Zacks.com
Alexion's Strensiq and Kanuma Get Positive CHMP Opinions - Analyst Blog
Jun 29 / Zacks.com
Portola, Bristol-Myers and Pfizer Report Encouraging Data - Analyst Blog
Jun 23 / Zacks.com
BioMarin DMD Drug Drisapersen Validated for EU Review - Analyst Blog
Jun 26 / Zacks.com
RedHill Biopharma (RDHL) Falls: Stock Goes Down 5.3% - Tale of the Tape
Jun 23 / Zacks.com
Bristol-Myers Announces Job Cuts, Changes in R&D Sites - Analyst Blog
Jun 26 / Zacks.com
Gilead Patent for Sovaldi Rejected in China, Shares Down - Analyst Blog
Jun 22 / Zacks.com
Zoetis Up as Valeant Rumored to be Interested in Buyout - Analyst Blog
Jun 26 / Zacks.com
Teva Announces Acquisition of 4.61% Interest in Mylan - Analyst Blog
Jun 22 / Zacks.com
Catalyst Pharmaceuticals Reports Tourette's Disorder Data - Analyst Blog
Jun 25 / Zacks.com
FibroGen (FGEN) Looks Good: Stock Moves 8.4% Higher - Tale of the Tape
Jun 22 / Zacks.com
Bayer Contraceptive Essure to Face FDA Panel on Complaints - Analyst Blog
Jun 25 / Zacks.com
Looking good: Botox maker buys double-chin treatment
Jun 17 / CNNMoney.com

To view my watchlist

Not a member yet?

Sign up now for a free account